Your browser doesn't support javascript.
loading
Defining benchmark outcomes for mesial temporal lobe epilepsy surgery: A global multicenter analysis of 1119 cases.
Drexler, Richard; Ricklefs, Franz L; Ben-Haim, Sharona; Rada, Anna; Wörmann, Friedrich; Cloppenborg, Thomas; Bien, Christian G; Simon, Matthias; Kalbhenn, Thilo; Colon, Albert; Rijkers, Kim; Schijns, Olaf; Borger, Valeri; Surges, Rainer; Vatter, Hartmut; Rizzi, Michele; de Curtis, Marco; Didato, Giuseppe; Castelli, Nicoló; Carpentier, Alexandre; Mathon, Bertrand; Yasuda, Clarissa Lin; Cendes, Fernando; Chandra, Poodipedi Sarat; Tripathi, Manjari; Clusmann, Hans; Delev, Daniel; Guenot, Marc; Haegelen, Claire; Catenoix, Hélène; Lang, Johannes; Hamer, Hajo; Brandner, Sebastian; Walther, Katrin; Hauptmann, Jason S; Jeffree, Rosalind L; Kegele, Josua; Weinbrenner, Eliane; Naros, Georgios; Velz, Julia; Krayenbühl, Niklaus; Onken, Julia; Schneider, Ulf C; Holtkamp, Martin; Rössler, Karl; Spyrantis, Andrea; Strzelczyk, Adam; Rosenow, Felix; Stodieck, Stefan; Alonso-Vanegas, Mario A.
Afiliação
  • Drexler R; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ricklefs FL; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ben-Haim S; Department of Neurosurgery, University of California, San Diego, San Diego, California, USA.
  • Rada A; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Wörmann F; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Cloppenborg T; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Bien CG; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Simon M; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Kalbhenn T; Department of Neurosurgery (Evangelisches Klinikum Bethel), Medical School, Bielefeld University, Bielefeld, Germany.
  • Colon A; Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Bielefeld, Germany.
  • Rijkers K; Department of Neurosurgery (Evangelisches Klinikum Bethel), Medical School, Bielefeld University, Bielefeld, Germany.
  • Schijns O; Department of Epileptology, Academic Center for Epileptology Kempenhaeghe, Heeze, the Netherlands.
  • Borger V; ACE Work Group Epilepsy Surgery Kempenhaeghe/Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Surges R; ACE Work Group Epilepsy Surgery Kempenhaeghe/Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Vatter H; Department of Neurosurgery, Academic Center for Epileptology UMC/Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Rizzi M; School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • de Curtis M; ACE Work Group Epilepsy Surgery Kempenhaeghe/Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Didato G; Department of Neurosurgery, Academic Center for Epileptology UMC/Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Castelli N; School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Carpentier A; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
  • Mathon B; Department of Epileptology, University Hospital Bonn, Bonn, Germany.
  • Yasuda CL; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
  • Cendes F; Department of Epileptology, University Hospital Bonn, Bonn, Germany.
  • Chandra PS; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
  • Tripathi M; Department of Epileptology, University Hospital Bonn, Bonn, Germany.
  • Clusmann H; Functional Neurosurgery Unit, Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Delev D; Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Guenot M; Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Haegelen C; Functional Neurosurgery Unit, Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Catenoix H; Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France.
  • Lang J; Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France.
  • Hamer H; Department of Neurology, University of Campinas, Campinas, Brazil.
  • Brandner S; Department of Neurology, University of Campinas, Campinas, Brazil.
  • Walther K; Department of Neurosurgery and Neurology, AIIMS, and MEG Resource Facility, New Delhi, India.
  • Hauptmann JS; Department of Neurosurgery and Neurology, AIIMS, and MEG Resource Facility, New Delhi, India.
  • Jeffree RL; Department of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany.
  • Kegele J; Department of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany.
  • Weinbrenner E; Department of Functional Neurosurgery, Hospital Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Naros G; Department of Functional Neurosurgery, Hospital Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Velz J; Department of Neurology, Hospices Civils de Lyon, Lyon, France.
  • Krayenbühl N; Epilepsy Center, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany.
  • Onken J; Epilepsy Center, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany.
  • Schneider UC; Epilepsy Center, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany.
  • Holtkamp M; Epilepsy Center, Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany.
  • Rössler K; Department of Neurosurgery, University of Washington, Seattle, Washington, USA.
  • Spyrantis A; Department of Neurosurgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Strzelczyk A; Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Rosenow F; Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Stodieck S; Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Alonso-Vanegas MA; Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Epilepsia ; 65(5): 1333-1345, 2024 May.
Article em En | MEDLINE | ID: mdl-38400789
ABSTRACT

OBJECTIVE:

Benchmarking has been proposed to reflect surgical quality and represents the highest standard reference values for desirable results. We sought to determine benchmark outcomes in patients after surgery for drug-resistant mesial temporal lobe epilepsy (MTLE).

METHODS:

This retrospective multicenter study included patients who underwent MTLE surgery at 19 expert centers on five continents. Benchmarks were defined for 15 endpoints covering surgery and epilepsy outcome at discharge, 1 year after surgery, and the last available follow-up. Patients were risk-stratified by applying outcome-relevant comorbidities, and benchmarks were calculated for low-risk ("benchmark") cases. Respective measures were derived from the median value at each center, and the 75th percentile was considered the benchmark cutoff.

RESULTS:

A total of 1119 patients with a mean age (range) of 36.7 (1-74) years and a male-to-female ratio of 11.1 were included. Most patients (59.2%) underwent anterior temporal lobe resection with amygdalohippocampectomy. The overall rate of complications or neurological deficits was 14.4%, with no in-hospital death. After risk stratification, 377 (33.7%) benchmark cases of 1119 patients were identified, representing 13.6%-72.9% of cases per center and leaving 742 patients in the high-risk cohort. Benchmark cutoffs for any complication, clinically apparent stroke, and reoperation rate at discharge were ≤24.6%, ≤.5%, and ≤3.9%, respectively. A favorable seizure outcome (defined as International League Against Epilepsy class I and II) was reached in 83.6% at 1 year and 79.0% at the last follow-up in benchmark cases, leading to benchmark cutoffs of ≥75.2% (1-year follow-up) and ≥69.5% (mean follow-up of 39.0 months).

SIGNIFICANCE:

This study presents internationally applicable benchmark outcomes for the efficacy and safety of MTLE surgery. It may allow for comparison between centers, patient registries, and novel surgical and interventional techniques.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benchmarking / Epilepsia do Lobo Temporal Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Epilepsia Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benchmarking / Epilepsia do Lobo Temporal Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Epilepsia Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha